{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 18/80', 'Endpoints:', 'Primary Endpoint', '-', 'Change from baseline in mRSS over 24 weeks', 'Secondary Endpoint', '- Incidence of treatment-emergent adverse events (TEAEs), serious adverse events', '(SAEs), adverse events (AEs), and tolerability of GLPG1690 over 24 weeks', 'Other Endpoints', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 19/80', '2.', 'INTRODUCTION', \"For more details refer to the investigator's brochure (IB) for GLPG1690 (Edition 6, 28-Jun-\", '2019) and relevant updates/addenda.', 'This clinical study will be conducted in accordance with the current International Council for', 'Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good', 'Clinical Practice (ICH-GCP) Guideline E6 (see also Section 10).', 'Systemic Sclerosis', 'Systemic sclerosis (scleroderma) is a rare autoimmune disease of the connective tissue with the', 'highest mortality rate of all rheumatic diseases. The disease has a female predominance (3:1)', 'and a peak onset in the fourth decade of life. Systemic sclerosis has three major pathogenic', 'components: (i) fibrosis with thickening of the skin and inner organs, (ii) inflammation, and', '(iii) vasculopathy. Major organs affected are the skin, the lung (pulmonary fibrosis and', 'pulmonary arterial hypertension), the kidneys, the gastrointestinal tract, the musculoskeletal', 'system, the retroperitoneal space, and the heart. Current treatment options for systemic sclerosis', 'are limited and include topical skin treatments, non-steroidal anti-inflammatory drugs, steroids,', 'and other immunosuppressants (methotrexate, mycophenolate mofetil [MMF], azathioprine,', 'cyclophosphamide).', 'At present, there are no approved drugs for the treatment of systemic sclerosis, indicating a', 'high-level unmet medical need.', 'The sponsor is currently pursuing the development of GLPG1690, a small-molecule autotaxin', '(ATX) inhibitor targeting disease-relevant signal transduction pathways, for the treatment of', 'systemic sclerosis.', 'Mode of Action', 'GLPG1690 is a novel, potent, and selective small-molecule inhibitor of ATX.', 'ATX, also known as ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) 2', 'or', 'lysophospholipase D (LPD), is a ~120 kDa protein that belongs to the ENPP enzyme family.', 'ATX is the only ENPP enzyme with LPD activity and is responsible for the hydrolysis of', 'lysophosphatidylcholine (LPC) to produce the bioactive lipid lysophosphatidic acid (LPA). The', 'term LPA covers several chemical species able to activate LPA receptors depending on the', 'nature of the fatty acid side chain on the glycerol backbone. The most abundant LPA species in', 'human plasma is LPA C18:2 with a fatty acid side chain of 18 carbon atoms including', 'two unsaturated bonds (Bandoh K. et al, 2000). Literature data have identified the ATX/LPC', 'axis as the main source of LPA in blood (Tanaka M. et al., 2006; Tsuda S. et al., 2006).', 'LPA acts through six different G-protein coupled receptors (LPA1-6) whereby mainly LPA1-3', 'have been associated with the pathogenic (pro-inflammatory and pro-fibrotic) effects of LPA.', 'Targeting the ATX pathway by antagonizing LPA1 in a previous Phase 2a study (SAR100842)', 'in systemic sclerosis was well tolerated and resulted in clinical improvements of skin', 'pathologies (modified Rodnan skin score [mRSS]) and skin biomarkers, suggesting that', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 20/80', 'targeting the ATX pathway is promising in modulating skin pathologies in systemic sclerosis', '(Allanore T. et al., 2018).', 'Available literature and nonclinical pharmacology data generated by Galapagos suggest that', 'interventions targeting the ATX/LPA pathway could lead to a new class of therapy for disease', 'modification in systemic sclerosis.', '2.1.', 'BACKGROUND - NONCLINICAL STUDIES', '2.1.1. Physical, Chemical, Pharmaceutical Properties, and Formulation', 'The chemical name of GLPG1690 is 2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)', '-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl](methyl)amino]-4-(4-', 'fluorophenyl)-1,3-thiazole-5-carbonitrile.', 'The clinical formulation used in this study is a film-coated tablet.', '2.1.2. Pharmacology', '2.1.2.1.', 'Primary and Secondary Pharmacology', 'GLPG1690 is an ATX inhibitor (50% inhibitory concentration [IC50] of 131 nM and 224 nM', 'in biochemical assays with human enzyme and mouse enzyme, respectively). The', 'LPA production after human plasma incubation was inhibited by GLPG1690 with an IC50 of', '242 nM, demonstrating the low impact of plasma protein binding on the activity of the', 'compound. The compound was selective over related enzymes like ENPP1, phosphodiesterase', '(PDE)4 and PDE5, and phospholipase A (PLA) and phospholipase C (PLC). Moreover,', 'GLPG1690 showed no inhibition in a panel of kinases. In a Cerep diversity panel (98 targets', 'including receptors and ion channels), only three targets displayed more than 50% inhibition at', '10 uM,', 'GLPG1690 dose-dependently inhibited the production of connective tissue growth factor', '(CTGF), interleukin 6 (IL-6), and endothelin-1 (ET-1) upon transforming growth factor \u00df', '(TGFB)-triggering in normal human dermal fibroblasts and in lung fibroblasts from a subject', 'with idiopathic pulmonary fibrosis (IPF).', 'Pharmacokinetic (PK)/pharmacodynamic (PD) experiments in mice demonstrated an inverse', 'relationship between LPA level and GLPG1690 concentration in plasma in vivo.', 'The efficacy of GLPG1690 was assessed in a murine model of chronic graft-versus-host disease', '(cGvHD) resembling key components of dermal and pulmonary systemic sclerosis disease', 'manifestations by evaluating clinical scoring, dermal thickening, hydroxyproline content, and', 'myofibroblast counts. In this model, GLPG1690 showed efficacy for skin and lung read-out', 'parameters similar to that of nintedanib.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}